Navigatie
Marktvooruitzichten Voorraadscreener Dividend kalender Evenementen kalender Waardering van aandelen Markten Nieuws
Probeer gratis

FibroGen

NASDAQ FGEN
$1.20 -0.04 -3.33%
Today share price
VS
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Показатель: 15 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

118.78M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
91.14M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.99
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
98.98M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
35.39 %

Upcoming events FibroGen

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart FibroGen

Stock analysis FibroGen

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-0.49 28.88
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
-0.58 4.03
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.40 11.32
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.12 0.25
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
105.41 10.75

Price change FibroGen per year

9.88$ 57.21$
Min Max

Summary analysis FibroGen

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure FibroGen

Revenue and net income FibroGen

All parameters

Stock news FibroGen

All news
30 augustus 2023 в 15:00

FibroGen shares fall after failure in late-stage study of Duchenne muscular dystrophy treatment

30 augustus 2023 в 02:10

Stocks to Watch: FibroGen, Box

30 augustus 2023 в 02:10

Stocks to Watch: FibroGen, Box

29 augustus 2023 в 23:50

FibroGen Shares Sink 16% on Pamrevlumab Study Not Meeting Primary Endpoint

29 augustus 2023 в 23:50

FibroGen Shares Sink 16% on Pamrevlumab Study Not Meeting Primary Endpoint

25 juli 2023 в 14:35

FibroGen Taps Thane Wettig as Interim CEO on Conterno Exit

25 juli 2023 в 14:30

FibroGen Taps Thane Wettig as Interim CEO on Conterno Exit

27 juni 2023 в 20:35

FibroGen Shares Keep Dropping, Hit 52-Week Low

27 juni 2023 в 20:35

FibroGen Shares Keep Dropping, Hit 52-Week Low

26 juni 2023 в 20:45

FibroGen Shares Hit 52-Week Low After Pamrevlumab Trial Misses Primary Endpoint

26 juni 2023 в 20:45

FibroGen Shares Hit 52-Week Low After Pamrevlumab Trial Misses Primary Endpoint

26 juni 2023 в 14:55

FibroGen Shares Drop 74% After Pamrevlumab Trial Misses Primary Endpoint

26 juni 2023 в 14:55

FibroGen Shares Drop 74% After Pamrevlumab Trial Misses Primary Endpoint

26 juni 2023 в 14:20

FibroGen to discontinue late-stage trial of treatment for idiopathic pulmonary fibrosis, cut costs to extend cash runway to 2026

7 juni 2023 в 15:15

FibroGen shares slide after Duchenne muscular dystrophy treatment falls short in trial

7 juni 2023 в 14:20

FibroGen Shares Down 14.5% After Muscular Dystrophy Treatment Trial Misses Endpoint

7 juni 2023 в 14:20

FibroGen Shares Down 14.5% After Muscular Dystrophy Treatment Trial Misses Endpoint

5 mei 2023 в 15:45

FibroGen Shares Fall After Roxadustat Misses Primary Endpoint

5 mei 2023 в 15:45

FibroGen Shares Fall After Roxadustat Misses Primary Endpoint

4 oktober 2021 в 17:05

What’s Happening With FibroGen Stock?

About company FibroGen

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Address:
409 Illinois Street, San Francisco, CA, United States, 94158
Company name: FibroGen
Issuer ticker: FGEN
ISIN: US31572Q8087
Country: VS
Exchange: NASDAQ
Currency: $
IPO date: 2014-11-14
Sector: Healthcare
Industry: Biotechnology
Site: https://www.fibrogen.com

On which stock exchange are FibroGen (FGEN) stocks traded?

FibroGen (FGEN) stocks are traded on NASDAQ.

What is the ticker of FibroGen stocks (FGEN)?

The stock ticker of FibroGen’s stocks or in other words, the code is FGEN. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does FibroGen (FGEN) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, FibroGen (FGEN) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are FibroGen (FGEN) stocks traded?

FibroGen (FGEN) stocks are traded on the NASDAQ exchange in dollars.

What is the price of FibroGen (FGEN) stocks today?

The current price of FibroGen stocks on 20.05.2024 is 1.2 dollars. per share.

What is the dynamics of FibroGen (FGEN) stocks from the beginning of the year?

FibroGen (FGEN) quotes have increased by 44.47% from the beginning of the year up to 1.2 dollars. per 1 stocks.

How much did FibroGen (FGEN) stocks increase in мае 2024?

This month FibroGen (FGEN) quotes have increased by 2.56% to 1.2 dollars. per share.

How much are FibroGen (FGEN) stocks worth?

Today, on October, 20.05.2024 FibroGen’s (FGEN) stocks cost 1.2 dollars..

What is the market capitalization of FibroGen (FGEN)?

Capitalization is the market value of FibroGen (FGEN) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 20.05.2024, the market capitalization of FibroGen (FGEN) is estimated at about 118778400 dollars.